Form 4: Veracyte CFO Sells Shares Under Pre-Arranged Plan

Veracyte's Chief Financial Officer, Rebecca Chambers, reported the sale of 13,278 shares of common stock and tax-related withholding of 3,384 shares, all under a pre-arranged 10b5-1 plan.

Summary

• Rebecca Chambers, Veracyte's Chief Financial Officer, reported changes in her beneficial ownership of common stock.
• On December 2, 2025, 3,384 shares of common stock were withheld at a price of $46.16 to satisfy tax withholding obligations related to the vesting of restricted stock units. This transaction does not represent a sale.
• On December 4, 2025, Chambers sold 8,537 shares of common stock at a weighted average price of $46.6143, with individual sale prices ranging from $46.04 to $47.03.
• Also on December 4, 2025, an additional 4,741 shares of common stock were sold at a weighted average price of $47.2493, with individual sale prices ranging from $47.05 to $47.51.
• Both sales on December 4, 2025, were executed pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on August 21, 2025.
• Following these reported transactions, Chambers beneficially owns 109,496 shares of Veracyte common stock.

Sentiment

Score: 5

Explanation: Neutral. The filing reports routine insider transactions, including tax withholding and pre-planned sales under a 10b5-1 plan, which are not typically indicative of significant positive or negative company-specific news.

Positives

• The reported sales were conducted under a pre-arranged Rule 10b5-1 plan, indicating planned liquidity and diversification rather than opportunistic selling based on new material non-public information.

Negatives

• Chief Financial Officer Rebecca Chambers disposed of a total of 13,278 shares of common stock through sales, which represents a reduction in her direct ownership.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Sales of common stock by Chief Financial Officer Rebecca Chambers.
• Tax withholding of common stock related to RSU vesting for Chief Financial Officer Rebecca Chambers.

Stakeholder Impact

• Shareholders: The sale of shares by a CFO, even if pre-planned, could be interpreted by some shareholders as a signal, though the existence of a 10b5-1 plan mitigates concerns about opportunistic selling. The overall impact is likely minimal given the routine nature of such disclosures.

Key Dates

Recommendation

This filing is a routine Form 4 disclosing insider transactions by the CFO, including tax withholding and sales under a pre-arranged 10b5-1 plan. These transactions do not provide new fundamental information about the company's operations or future prospects that would warrant a change in investment recommendation. Investors should continue to hold based on broader company fundamentals rather than these standard disclosures.

Keywords

Veracyte, VCYT, SEC Form 4, Insider Trading, Rebecca Chambers, Chief Financial Officer, Stock Sale, 10b5-1 Plan, Restricted Stock Units, Tax Withholding